Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.50 |
| ▸ | RXRB | P28702 | 9/20 | 0.50 |
| ▸ | RXRG | P48443 | 9/20 | 0.50 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865218 | 0.90 | ALDH1A1 (0.44) | RXRARXRBRXRGILKEPHX2 | |
| SCHEMBL3870144 | 0.77 | RXRA (0.56) | RXRARXRBRXRGILKEPHX2 | |
| SCHEMBL3864045 | 0.77 | EPHX2 (0.61) | RXRARXRBRXRGEPHX2PTGS2 | |
| SCHEMBL3870918 | 0.76 | PTGS2 (0.44) | RXRAEPHX2PTGS2ALDH1A1LMNA | |
| SCHEMBL3865539 | 0.73 | CHRNA7 (0.41) | PTGS2CYP2C9KDM4EALDH1A1LMNA | |
| SCHEMBL3865955 | 0.70 | PTGS2 (0.48) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL15560871 | 0.68 | RXRA (0.62) | RXRARXRBRXRGILKEPHX2 | |
| SCHEMBL3865209 | 0.68 | ILK (0.52) | RXRARXRBRXRGILKEPHX2 | |
| SCHEMBL14728118 | 0.67 | RXRA (0.80) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL6014018 | 0.65 | PTGS2 (0.72) | PTGS2CYP2C9ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7442802-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7087630-B2 | Cyclooxygenase 2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885 |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885 |
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTGS2, PTGIS, PTGES2 | RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.